Diversified Trust Co Purchases Shares of 1,508 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Diversified Trust Co acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,508 shares of the company's stock, valued at approximately $633,000.

Other institutional investors have also recently made changes to their positions in the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth about $29,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $30,000. Colonial Trust Co SC raised its holdings in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the period. Itau Unibanco Holding S.A. boosted its position in IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC grew its holdings in IDEXX Laboratories by 40.0% in the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after purchasing an additional 30 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $5.02 during midday trading on Monday, hitting $536.34. The company had a trading volume of 471,081 shares, compared to its average volume of 645,066. The business's 50-day simple moving average is $499.01 and its 200-day simple moving average is $450.94. The stock has a market cap of $43.13 billion, a price-to-earnings ratio of 49.57, a price-to-earnings-growth ratio of 3.88 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $536.87.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the previous year, the firm earned $2.71 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. On average, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 11th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $546.00.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director directly owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.98% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.